-
Uncategorized2 months agoFDA again spurns Replimune melanoma drug
The decision, which has been a flashpoint in an ongoing debate about regulatory flexibility, was made because Replimune failed to address the agency’s issues with the...
-
Uncategorized2 months ago
Drugs from a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
From designing drugs with a simple text prompt to running experiments guided by extended reality, a new wave of agentic AI is transforming the modern lab....
-
Uncategorized2 months agoGAO report shows gap between scale of illegal vapes and enforcement
With thousands of illegal e-cigarettes for sale in the U.S., both the Trump and Biden administrations have vowed to crack down on the illicit fruit- and...
-
Uncategorized2 months agoSTAT+: Replimune skin cancer drug that became FDA flashpoint is rejected again
The Food and Drug Administration on Friday rejected — again — an experimental treatment for advanced skin cancer developed by Replimune Group. Replimune’s treatment, an engineered...
-
Uncategorized2 months ago
Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option
New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the...
-
Uncategorized2 months agoTrump administration admits a glaring error in its accusations about New York health care fraud
NEW YORK — President Donald Trump’s administration this week acknowledged it made a significant error in figures it used to help justify a fraud probe into New York’s...
-
Uncategorized2 months ago
FDA rejects Replimune’s melanoma prospect for second time
The second time is not the charm for Replimune’s melanoma candidate RP1. After spurning the immunotherapy last July, the FDA has now rejected the biotech’s resubmitted...
-
Uncategorized2 months agoSTAT+: GSK says goodbye to leucovorin (again)
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Buyer beware: If you are an avid consumer...
-
Uncategorized2 months agoThis week in Drug Discovery (6 – 10 April)
News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW. This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition....
-
Uncategorized2 months ago
Novo’s double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
